Beam Therapeutics Inc.
As of Oct 22, 2026, Beam Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 14, 2026). It closed at $24.56, 35.2% below its 52-week high and below its 200-day average, which is falling.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BEAM early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BEAM among Biotechnology237th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …237 | BEAM | Stage 4 · wk 6 | 41 | +0.8% |
Beam Therapeutics: quick answers
What stage is Beam Therapeutics in?
As of Oct 22, 2026, Beam Therapeutics (BEAM) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 14, 2026 and is in week 6. What the four stages mean
Is Beam Therapeutics in an uptrend?
No. Beam Therapeutics is in a Stage 4 downtrend. It trades 13.2% below its 200-day average, which is falling.
How far is Beam Therapeutics from its 52-week high?
Beam Therapeutics closed at $24.56 on Oct 22, 2026, 35.2% below its 52-week high of $37.92. Its 52-week low is $20.60.
How has Beam Therapeutics performed over the past year?
As of Oct 22, 2026, Beam Therapeutics is down 17.8% over the past year and down 9.5% so far in 2026.
Which sector and industry is Beam Therapeutics in?
Beam Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.